June 4, 2023

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Masahiro Tsuboi

Roy S. Herbst

Thomas John

Journals

New England Journal of Medicine

Actions

Institutions

University of California, Los Angeles

The University of Melbourne

Shanghai Jiao Tong University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study